Ewelina Weglarz-Tomczak (UvA): Lysosomal protease inhibitors for Alzheimer’s
Ewelina Weglarz-Tomczak (UvA): Novel lysosomal protease inhibitors for the treatment of Alzheimer’s disease
Highly specified proteases are the key regulators in the molecular mechanism of neurodegeneration in Alzheimer’s disease. AI-powered technology developed by NatInLab has led to the discovery of how those proteases are controlled in the human organism. Based on this knowledge, developing novel, highly effective and safe inhibitors of these proteases is possible. The project aims to deliver new agents against Alzheimer’s and possibly other neurodegenerative diseases as the next step. The novel drugs are expected to be curative and show minimal side effects.
Explore other Cases:
John van der Kamp and Boris Lancelot (VU): Lentala
John van der Kamp and Boris Lancelot (VU): Rom & Lupa designed by Lentala: school furniture for active sitting Today, children move too little and sit too much, especially a school classrooms. Prolonged passive sitting is a risk factor for poor physical health and low mental well-being. The human body has evolved to move and […]
Job Calis (Amsterdam UMC) and Mark Hoogendoorn (VU): IMPALA
Job Calis (Amsterdam UMC) and Mark Hoogendoorn (VU): IMPALA: Innovative Monitoring system for PAediatrics in Low-resource settings: an Aid to save lives. Each year, more than 3 million children die in poor countries. At least half of these deaths can be prevented by early recognition, before patients deteriorate. In Europe, patient monitors are used to […]
Siwan Aberkane (VU): PULSE Sports
Siwan Aberkane (VU): PULSE Sports – App-connected sportswear allowing athletes to monitor their body & mind, to maximise performance & avoid over-training. Millions of athletes worldwide are in a crisis, struggling with extreme physical and mental issues. Research experts and athletes themselves confirme that existing tools are too superficial and inaccurate for the prevention of […]